Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE)

Next Previous
Trial Profile

Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RADAR; RADAR (UK-MRA Myeloma XV)

Most Recent Events

  • 12 Dec 2023 Trial design, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 12 Dec 2023 Results assessing patient-reported outcomes from participants enrolling in the RADAR study to understand the HRQoL of MM patients in different subgroups prior to treatment, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top